ZOMIG-ZMT Drug Patent Profile

When do Zomig-zmt patents expire, and what generic alternatives are available?

Zomig-zmt is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zomig-zmt

A generic version of ZOMIG-ZMT was approved as zolmitriptan by GLENMARK PHARMS LTD on May 14^th, 2013.

Summary for ZOMIG-ZMT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	80
Patent Applications:	4,677
DailyMed Link:	ZOMIG-ZMT at DailyMed

US Patents and Regulatory Information for ZOMIG-ZMT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca	ZOMIG-ZMT	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	021231-001	Feb 13, 2001		DISCN	Yes	No
Astrazeneca	ZOMIG-ZMT	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	021231-002	Sep 17, 2001		DISCN	Yes	No

Expired US Patents for ZOMIG-ZMT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca	ZOMIG-ZMT	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	021231-001	Feb 13, 2001
Astrazeneca	ZOMIG-ZMT	zolmitriptan	TABLET, ORALLY DISINTEGRATING;ORAL	021231-002	Sep 17, 2001

International Patents for ZOMIG-ZMT

See the table below for patents covering ZOMIG-ZMT around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	100215627
New Zealand	238424	3,5-SUBSTITUTED INDOLE DERIVATIVES; MEDICAMENTS AND PREPARATORY PROCESSES.
Luxembourg	90205
Egypt	19650	Derivatives of indol and their use for treatment of megraine

Supplementary Protection Certificates for ZOMIG-ZMT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0463756	300048	Netherlands		PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
0486666	72/1997	Austria		PRODUCT NAME: ZOLMITRIPTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ZULAESSIGEN SALZES; NAT. REGISTRATION NO/DATE: 1-22068, 1-22069 19970819; FIRST REGISTRATION: GB 12619/0116, 12619/0117 19970307
0486666	SPC/GB97/089	United Kingdom		PRODUCT NAME: ZOLMITRIPTAN AND OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 12619/0116 19970307
0486666	C980001	Netherlands		PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NAT. REGISTRATION NO/DATE: RVG 21079, RVG 21080 19970925; FIRST REGISTRATION: GB PL 12619/0116 19970307

ZOMIG-ZMT Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

ZOMIG-ZMT (zolmitriptan orally disintegrating tablet) is a prescription medication used for the acute treatment of migraine headaches. Its market performance is shaped by patent exclusivity, generic competition, and physician prescribing patterns.

What is the Patent Status of ZOMIG-ZMT?

ZOMIG-ZMT's primary patent protection has expired, opening the door for generic market entry. The U.S. Patent No. 5,789,003 for zolmitriptan was issued on August 4, 1998. This patent, along with others related to formulations and manufacturing processes, has since expired. The expiration of key patents allows for the introduction of lower-cost generic versions of the drug, impacting the pricing and market share of the branded product.

Who are the Key Manufacturers of ZOMIG-ZMT and its Generics?

The originator brand, Zomig-ZMT, was developed and marketed by AstraZeneca. Following patent expiry, several generic manufacturers have entered the market. These include, but are not limited to:

• Teva Pharmaceuticals
• Mylan Pharmaceuticals (now Viatris)
• Dr. Reddy's Laboratories
• Aurobindo Pharma

These companies produce generic zolmitriptan tablets, including orally disintegrating formulations, which directly compete with the branded Zomig-ZMT.

What is the Historical Sales Performance of ZOMIG-ZMT?

AstraZeneca reported sales for its migraine products, which include Zomig and Zomig-ZMT, prior to the widespread impact of generic competition. For instance, in fiscal year 2011, global sales for the Zomig franchise were approximately \$312 million. By fiscal year 2013, these sales had declined to approximately \$245 million, reflecting increasing generic penetration and price erosion in key markets. Post-2014, specific sales figures for the branded Zomig-ZMT become increasingly difficult to isolate as generic competition intensified and reporting shifted.

How Has Generic Competition Impacted ZOMIG-ZMT Pricing and Market Share?

The introduction of generic zolmitriptan has led to significant price reductions. Branded Zomig-ZMT, when available, typically commands a premium price compared to its generic equivalents. The market share of branded Zomig-ZMT has demonstrably decreased as payers and prescribers favor the more cost-effective generic options. For example, within months of generic launches, prices for zolmitriptan have often fallen by 50-80% compared to the branded product's peak pricing. This dynamic forces the branded product to compete on volume or niche market segments, if at all.

What is the Current Market Size and Growth Projection for Zolmitriptan?

Estimating the precise current market size for branded Zomig-ZMT is challenging due to limited separate reporting post-generic entry. The overall market for zolmitriptan, encompassing both branded and generic versions, is estimated to be in the low hundreds of millions of dollars globally.

Growth projections for the overall zolmitriptan market are generally modest. Factors influencing this include:

• Established Efficacy: Zolmitriptan remains an effective acute treatment for many migraine sufferers.
• Competition from Newer Migraine Therapies: The emergence of CGRP inhibitors and gepants offers new treatment paradigms, potentially drawing market share from older triptans.
• Generic Price Erosion: Continued price competition among generic manufacturers limits overall market value growth.

The market is largely driven by the volume of prescriptions, with growth primarily attributable to increasing patient access to generics.

What are the Regulatory Considerations for ZOMIG-ZMT and its Generics?

Regulatory approval for both the branded Zomig-ZMT and its generic versions is managed by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Generic drugs must demonstrate bioequivalence to the reference listed drug (RLD), which is Zomig-ZMT in this case. This means the generic formulation must deliver the same amount of active ingredient to the bloodstream over the same period as the branded product.

Post-market surveillance remains a regulatory concern. This includes monitoring for adverse events, manufacturing quality, and labeling compliance for all approved zolmitriptan products. Changes to manufacturing processes or formulations by generic manufacturers require regulatory review.

What are the Reimbursement Landscapes for ZOMIG-ZMT?

Reimbursement for ZOMIG-ZMT and its generic equivalents is determined by pharmacy benefit managers (PBMs), insurance companies, and national health systems.

• Branded Zomig-ZMT: Reimbursement for the branded product has become less favorable as generic alternatives have gained formulary preference. Some payers may require prior authorization or step-therapy protocols, where patients must try generics first.
• Generic Zolmitriptan: Generic zolmitriptan is typically listed on formularies with lower co-pays, making it the preferred option for most insurance plans and patients. The cost differential is a primary driver of prescribing behavior.

The trend favors widespread coverage for generic zolmitriptan due to its cost-effectiveness.

What is the Competitive Landscape for ZOMIG-ZMT?

ZOMIG-ZMT competes within the broader acute migraine treatment market, specifically among the triptan class and newer therapeutic categories.

Direct Competition (Triptans):

• Sumatriptan (Imitrex)
• Zolmitriptan (generics)
• Rizatriptan (Maxalt)
• Almotriptan (Axert)
• Naratriptan (Amerge)
• Frovatriptan (Frova)
• Eletriptan (Relpax)

Indirect Competition (Newer Therapies):

• CGRP Inhibitors: Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Emgality) – Primarily for migraine prevention, but impacting the overall migraine market.
• Gepants: Ubrogepant (Ubrelvy), Rimegepant (Nurtec ODT) – Oral CGRP receptor antagonists for acute treatment, directly competing with triptans.
• Ditans: Lasmiditan (Reyvow) – A selective serotonin 5-HT1F receptor agonist for acute treatment.

The introduction of gepants and ditans represents a significant competitive shift, offering alternative mechanisms of action to triptans, which may have cardiovascular contraindications.

What are the Future Market Prospects for Zolmitriptan?

The future market for zolmitriptan is expected to remain stable in terms of volume but will likely see continued price pressure and a decreasing share of overall migraine treatment revenue.

• Continued Generic Dominance: Generic zolmitriptan will continue to be the primary form prescribed due to cost.
• Erosion by Newer Agents: Gepants and other novel acute migraine treatments will likely capture increasing market share, particularly for patients who do not respond well to or cannot tolerate triptans.
• Niche Use: Zomig-ZMT (and its generic orally disintegrating forms) will likely retain a role for patients who benefit from rapid onset of action and prefer the disintegrating tablet formulation for convenience, especially if they experience nausea or difficulty swallowing during a migraine.

The overall market for acute migraine treatments is evolving, with a trend towards targeted therapies and combinations addressing different patient needs and migraine profiles. Zolmitriptan, as a well-established and cost-effective option, will likely persist as a foundational therapy for a significant patient segment.

---

Key Takeaways

• ZOMIG-ZMT, an orally disintegrating tablet formulation of zolmitriptan, has expired patent protection, leading to substantial generic competition.
• Generic versions have significantly reduced pricing and captured the majority of market share from the branded product.
• The overall zolmitriptan market is characterized by modest growth, driven by generic volume rather than price increases.
• Newer acute migraine therapies, including gepants and ditans, represent increasing competition, potentially impacting the long-term market position of older triptans.
• Reimbursement landscapes strongly favor generic zolmitriptan due to cost-effectiveness, while branded Zomig-ZMT faces more restrictive coverage.

---

Frequently Asked Questions

1. What is the primary mechanism of action for zolmitriptan? Zolmitriptan is a selective serotonin receptor agonist that works by constricting blood vessels in the brain and blocking pain pathways, which helps relieve migraine symptoms.

2. Are there any significant contraindications for zolmitriptan use? Yes, zolmitriptan is contraindicated in patients with a history of ischemic heart disease, such as myocardial infarction or documented silent ischemia, or in patients with symptoms or signs of ischemic heart disease. It is also contraindicated in uncontrolled hypertension and in patients with peripheral vascular disease.

3. How does the orally disintegrating tablet (ODT) formulation of zomig differ from standard tablets? The ODT formulation dissolves on the tongue without water, offering a faster absorption profile for some patients and convenience for those who experience nausea or vomiting during a migraine and have difficulty swallowing pills.

4. What is the typical therapeutic response time for ZOMIG-ZMT? ZOMIG-ZMT typically provides relief within 30 to 60 minutes for a significant percentage of patients.

5. Can ZOMIG-ZMT be used for migraine prevention? No, ZOMIG-ZMT is indicated for the acute treatment of migraine headaches and is not used for migraine prevention.

---

Citations

[1] U.S. Food & Drug Administration. (1998). U.S. Patent 5,789,003. Retrieved from USPTO Patent Database. [2] AstraZeneca PLC. (2012). AstraZeneca Annual Report and Form 20-F 2011. [3] AstraZeneca PLC. (2014). AstraZeneca Annual Report and Form 20-F 2013. [4] Various generic drug manufacturer websites and public disclosures regarding product availability and pricing. [5] Market research reports on the migraine therapeutics market (proprietary data access required for specific figures). [6] U.S. Food & Drug Administration. (n.d.). Orange Book. Retrieved from FDA Drug Database. [7] Pharmaceutical industry news and analysis regarding new drug approvals and market entry strategies.